Table 12.

Clinical outcomes of polymer paclitaxel and paclitaxel therapy in patients with non-small cell lung cancer.

Treatment	N	Response rate	Median TTP	Median OS	1-year survival	Ref.
		(%)	(months)	(months)	(%)
		Polymer-paclitaxel Therapeutics
PG-PTXa	191	11	2.9	7.3	26	[46]
PG-PTX/Carboplatinb	199	20	3.9	7.8	31	[48]
PG-PTXc	427	8	2	6.9	25	[47]
Genexol-PM/Cisplatind	69	38	5.8	21.7	60	[49]
Paclitaxel Therapeutics
Paclitaxel/Carboplatine	201	37	4.6	7.9	31	[48]
Paclitaxel/Carboplatinf	81	32	-	6.6	16	[42]
Paclitaxel/Carboplating	80	36	-	8.7	27	[42]
Paclitaxel/Cisplatinh	38	62	5.5	13.7	57	[43]
Paclitaxel/Cisplatini	302	28	4.2	9.8	38	[44]
Paclitaxel/Carboplatinj	306	25	3	8.5	33	[44]
Paclitaxel/Carboplatink	206	25	4	8.6	38	[45]

^aPatients with advanced NSCLC, PS 2 on ECOG scale, received PPX (paclitaxel) at 175 mg/m² every 21 days, up to 6 cycles;

^bPatients with advanced NSCLC, PS 2 on ECOG scale, received PPX (paclitaxel) at 210 mg/m² in combination with carboplatin (AUC = 6) every 21 days, up to 6 cycles;

^cPatients with advanced NSCLC, PS 0-1 on ECOG scale, received PPX (paclitaxel) at 210 mg/m² every 21 days, and at 175 mg/m² every 21 days for PS 2 patients;

^dPatients with advanced NSCLC, PS 0-2 on ECOG scale, received Genexol-PM (paclitaxel) at 200 mg/m² (3-h i.v. infusion), followed by cisplatin at 60 mg/m²,with standard hypersensitivity reaction premedications;

^ePatients with advanced NSCLC, PS 2 on ECOG scale, received paclitaxel at 225 mg/m² in combination with carboplatin (AUC = 6) every 21 days, up to 6 cycles, with standard hypersensitivity reaction pre-medications;

^fPatients with advanced stage IIIB or IV NSCLC, received four cycles of carboplatin at AUC of 6 and paclitaxel at 225 mg/m² over 3 h every 21 days, with standard hypersensitivity reaction pre-medications;

^gPatients with advanced stage IIIB or IV NSCLC, received four cycles of carboplatin at AUC of 6 and paclitaxel at 75 mg/m²/week for 12 weeks, with standard hypersensitivity reaction pre-medications;

^hPatients with advanced stage IIIB or IV NSCLC, PS 0-2 on ECOG scale, received paclitaxel at a starting dose of 40 mg/m² (1-h intravenous infusion) on days 1, 8, and 15, followed by cisplatin at a fixed dose of 80 mg/m², with standard hypersensitivity reaction pre-medications. The treatment was given in a 4-week cycle;

ⁱPatients with advanced stage IIIB or IV NSCLC, PS 0-2 on ECOG scale, received paclitaxel at 200 mg/m² (3-h intravenous infusion), followed by cisplatin at a dose of 80 mg/m² (30-min i.v. infusion), with standard hypersensitivity reaction pre-medications;

^jPatients with advanced stage IIIB or IV NSCLC, PS 0-2 on ECOG scale, received paclitaxel at 200 mg/m² (3-h i.v. infusion), followed by carboplatin at AUC of 6 (30-min i.v. infusion), with standard hypersensitivity reaction pre-medications;

^kPatients with advanced stage IIIB or IV NSCLC, PS 0-1 on ECOG scale, received paclitaxel at 225 mg/m² over 3 h with carboplatin at AUC of 6, every 21 days, with standard hypersensitivity reaction to pre-medications